Recognify’s Schizophrenia Drug Trial Misses Primary Target but Shows Positive Trends

Recognify Life Sciences, a subsidiary of atai Life Sciences, announced that its Phase IIb trial of inidascamine (RL-007) for cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint. The randomized, placebo-controlled, six-week study involved 242 participants across the US and Europe, assessing two doses of the drug against placebo using the MCCB neurocognitive composite score. While the trial failed to reach statistical significance, consistent numerical improvements were observed across MCCB scores and specific subdomains, such as symbol coding, processing speed, and verbal learning.

Positive trends also appeared in the VRFCAT, which measures functional cognitive capacity. The treatment was well tolerated, showing no weight gain, sedation, or extrapyramidal symptoms. CEO Matt Pando noted optimism from the replicable cognitive gains. The company is now analyzing secondary endpoints to explore potential responder profiles for future development. Schizophrenia is characterized by hallucinations, delusions, and disordered thinking.

31-08-2025